Single-staged in vivo co-transplantation of autologous muscular and urothelial micrografts as a composite tissue tube for urogenital reconstruction
Clausen AG., Juul N., Amoushahi M., Willacy O., Fossum M.
Animal Study, published in Pediatr Surg Int (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Pediatr Surg Int (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41511495
- PMCID
- PMC12789135
- DOI
- 10.1007/s00383-025-06259-5
- Citations
- 2
Abstract (original English)
PURPOSE: Tissue-engineered grafts conventionally rely on resource-intensive ex vivo cellularization. Perioperative autologous micrografting allows for direct single-staged graft cellularization omitting laboratory-based in vitro propagation. For urogenital reconstruction, where a muscular layer may be desirable, co-transplanting muscular and urothelial micrografts has previously shown to inhibit urothelial micrograft expansion. This study aimed to assess the effects of adding muscular micrografts in a separate compartment in a tubular collagen-based urinary graft. METHODS: Autologous tissue from twelve minipig bladders was used for implanting tubular grafts that were constructed and implanted subcutaneously as a single-staged in vivo procedure. Each animal received four grafts: two containing urothelial micrografts only (urothelial group) and two containing both urothelial and detrusor muscle micrografts (co-transplanted group). RESULTS: Six weeks post-implantation, 74% of the urothelial group and 64% of the co-transplanted tubular grafts demonstrated luminal pancytokeratin-positive epithelium (p = 0.524). Grafts were analyzed histologically and by immunoassays for identification of epithelium (pancytokeratin), differentiated urothelium (uroplakin II), smooth muscle (α-SMA & desmin), inflammation (CD68 & apoptosis assay), and vascularization (CD31+ vessels). No significant diff
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.